1例超高龄新型冠状病毒肺炎并发急性心力衰竭的抢救经验及文献回顾

黄惠风; 虞敏; 周任

doi:10.16766/j.cnki.issn.1674-4152.002925

1例超高龄新型冠状病毒肺炎并发急性心力衰竭的抢救经验及文献回顾

doi: 10.16766/j.cnki.issn.1674-4152.002925

黄惠风¹,
虞敏²,
周任^3, ,

1.
上海市青浦区朱家角人民医院内科，上海 200017
2.
上海交通大学医学院附属第一人民医院心脏及大血管外科，上海 200080
3.
上海交通大学医学院附属瑞金医院上海血液学研究所，医学基因组学国家重点实验室，转化医学国家重大科技基础设施(上海)，上海 200025

详细信息

通讯作者:
周任，E-mail: 862722617@qq.com

中图分类号: R563.1 R541.6
计量
- 文章访问数: 215
- HTML全文浏览量: 102
- PDF下载量: 16
- 被引次数: 0
出版历程
- 收稿日期: 2022-06-02
- 网络出版日期: 2023-04-19

Treatment of coronavirus disease 2019 complicated with acute heart failure of a super-elderly patient: a case report and literature review

HUANG Huifeng¹,
YU Min²,
ZHOU Ren^{3
, ,}

1.
Department of Internal Medicine, Qingpu Zhujiajiao People' s Hospital, Shanghai 200017, China

摘要

摘要: 2022年春季新型冠状病毒Omicron变异株在上海爆发了大流行。合并各类基础疾病的老年患者疫苗接种率较低，是本次流行的主要易感人群，且易进展为危重症。因此救治老年危重患者成为目前临床诊疗新型冠状病毒肺炎的难点之一。本报道是1例超高龄新型冠状病毒肺炎患者, 病程由轻症进展为重症，并发急性心力衰竭、心源性休克。笔者结合文献回顾性分析其病因和临床特征，分享基层医院诊疗高龄新型冠状病毒肺炎危重症的经验与得失，为救治新型冠状病毒肺炎危重症合并心血管并发症提供参考依据。
- 新型冠状病毒肺炎 /
- 高龄 /
- 急性心力衰竭 /
- 心肌损伤
Abstract: In the spring of 2022, a pandemic outbreak of the Omicron variant of SARS-CoV-2 occurred in Shanghai. The vaccination rate is low among elderly patients with various chronic underlying diseases, making them susceptible and prone to critical illnesses. Therefore, the treatment of elderly patients has become one of the difficulties in the clinical management of coronavirus disease 2019. This paper reported a case of a super-elderly patient diagnosed with coronavirus disease 2019 complicated with acute heart failure, whose disease progressed from mild to severe. We analysed the reliable aetiology and clinical features of the case and shared the gains and losses in the treatment of elderly patients with severe coronavirus disease 2019 in a primary care hospital. We planned to provide an important experience for the treatment of patients with coronavirus disease 2019 combined with cardiovascular complications.
- Coronavirus disease 2019 /
- Super-elderly /
- Acute heart failure /
- Myocardial injury

HTML全文

图 1 患者胸部肺窗CT影像结果

注：A~C为4月23日胸部CT；D~F为5月2日胸部CT；G~I为5月7日胸部CT。

Figure 1. Lung window CT images of the patient's chest

下载: 全尺寸图片幻灯片

图 2 患者5月2日休克发作时心电图

Figure 2. Electrocardiogram of the patient at the onset of shock on May 2

下载: 全尺寸图片幻灯片

图 3 患者实验室化验结果

注：A示体温及血细胞水平；B示cTnT及NT-proBNP水平；C示C反应蛋白、D-二聚体及肌酐水平；D示SARS-CoV-2核酸基因Ct值水平。

Figure 3. Laboratory test results of the patient

下载: 全尺寸图片幻灯片

参考文献(18)

[1]	MEO S A, MEO A S, AL-JASSIR F F, et al. Omicron SARS-CoV-2 new variant: global prevalence and biological and clinical characteristics[J]. Eur Rev Med Pharmacol Sci, 2021, 25(24): 8012-8018.
[2]	ZHANG X X, ZHANG W H, CHEN S J. Shanghai' s life-saving efforts against the current omicron wave of the COVID-19 pandemic[J]. Lancet, 2022, 399(10340): 2011-2012. doi: 10.1016/S0140-6736(22)00838-8
[3]	中国国家卫生健康委员会. 新型冠状病毒肺炎诊疗方案(试行第九版)[J]. 国际流行病学传染病学杂志, 2022, 49(2): 73-80. https://www.cnki.com.cn/Article/CJFDTOTAL-JSZY202204026.htm National Health Commission of the PRC. Diagnosis and treatment plan for COVID-19(trial version 9)[J]. International Journal of Epidemiological Epidemiology, 2022, 49(2): 73-80. https://www.cnki.com.cn/Article/CJFDTOTAL-JSZY202204026.htm
[4]	HAMMOND J, LEISTER-TEBBE H, GARDNER A, et al. Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19[J]. N Engl J Med, 2022, 386(15): 1397-1408. doi: 10.1056/NEJMoa2118542
[5]	孙露, 张弨. 胸腺肽类药物在新型冠状病毒肺炎应用中的思考[J]. 临床药物治疗杂志, 2020, 18(3): 63-67. https://www.cnki.com.cn/Article/CJFDTOTAL-LCYW202003013.htm SUN L, ZHANG C. Thoughts on the application of thymosin drugs in corona virus disease 2019[J]. Clinical Medication Journal, 2020, 18(3): 63-67. https://www.cnki.com.cn/Article/CJFDTOTAL-LCYW202003013.htm
[6]	ALI M, SPINLER S A. COVID-19 and thrombosis: from bench to bedside[J]. Trends Cardiovasc Med, 2021, 31(3): 143-160. doi: 10.1016/j.tcm.2020.12.004
[7]	王曦, 安松涛, 李文博, 等. 新型冠状病毒对循环系统影响的研究进展[J]. 中华全科医学, 2021, 19(2): 293-297. doi: 10.16766/j.cnki.issn.1674-4152.001792 WANG X, AN S T, LI W B, et al. Research progress of the effect of SARS-CoV-2 on the circulatory system[J]. Chinese Journal of General Practice, 2021, 19(2): 293-297. doi: 10.16766/j.cnki.issn.1674-4152.001792
[8]	BADER F, MANLA Y, ATALLAH B, et al. Heart failure and COVID-19[J]. Heart Fail Rev, 2021, 26(1): 1-10. doi: 10.1007/s10741-020-10008-2
[9]	ZHAO Y H, ZHAO L, YANG X C, et al. Cardiovascular complications of SARS-CoV-2 infection (COVID-19): a systematic review and meta-analysis[J]. Rev Cardiovasc Med, 2021, 22(1): 159-165. doi: 10.31083/j.rcm.2021.01.238
[10]	ONOHUEAN H, AL-KURAISHY H M, AL-GAREEB A I, et al. Covid-19 and development of heart failure: mystery and truth[J]. Naunyn Schmiedebergs Arch Pharmacol, 2021, 394(10): 2013-2021. doi: 10.1007/s00210-021-02147-6
[11]	CHEN L, HAO G. The role of angiotensin-converting enzyme 2 in coronaviruses/influenza viruses and cardiovascular disease[J]. Cardiovasc Res, 2020, 116(12): 1932-1936. doi: 10.1093/cvr/cvaa093
[12]	SIRIPANTHONG B, NAZARIAN S, MUSER D, et al. Recognizing COVID-19-related myocarditis: the possible pathophysiology and proposed guideline for diagnosis and management[J]. Heart Rhythm, 2020, 17(9): 1463-1471. doi: 10.1016/j.hrthm.2020.05.001
[13]	PENG X, WANG Y N, XI X W, et al. Promising therapy for heart failure in patients with severe COVID-19: calming the cytokine storm[J]. Cardiovasc Drugs Ther, 2021, 35(2): 231-247. doi: 10.1007/s10557-020-07120-8
[14]	SAWALHA K, ABOZENAH M, KADADO A J, et al. Systematic review of COVID-19 related myocarditis: insights on management and outcome[J]. Cardiovasc Revasc Med, 2021, 23: 107-113. doi: 10.1016/j.carrev.2020.08.028
[15]	LI Y, YU Y, CHEN S, et al. Corticosteroids and intravenous immunoglobulin in pediatric myocarditis: a meta-analysis[J]. Front Pediatr, 2019, 7: 342.
[16]	CAFORIO A L, PANKUWEIT S, ARBUSTINI E, et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases[J]. Eur Heart J, 2013, 34(33): 2636-2648.
[17]	HU H, MA F, WEI X, et al. Coronavirus fulminant myocarditis treated with glucocorticoid and human immunoglobulin[J]. Eur Heart J, 2021, 42(2): 206.
[18]	ZENG J H, LIU Y X, YUAN J, et al. First case of COVID-19 complicated with fulminant myocarditis: a case report and insights[J]. Infection, 2020, 48(5): 773-777.